Evaluation of diabetic foot ulcer healing with hyperspectral imaging of oxyhemoglobin and deoxyhemoglobin

Aksone Nouvong, Byron Hoogwerf, Emile Mohler, Brian Davis, Azita Tajaddini, Elizabeth Medenilla, Aksone Nouvong, Byron Hoogwerf, Emile Mohler, Brian Davis, Azita Tajaddini, Elizabeth Medenilla

Abstract

Objective: Foot ulceration remains a major health problem for diabetic patients and has a major impact on the cost of diabetes treatment. We tested a hyperspectral imaging technology that quantifies cutaneous tissue hemoglobin oxygenation and generated anatomically relevant tissue oxygenation maps to assess the healing potential of diabetic foot ulcers (DFUs).

Research design and methods: A prospective single-arm blinded study was completed in which 66 patients with type 1 and type 2 diabetes were enrolled and followed over a 24-week period. Clinical, medical, and diabetes histories were collected. Transcutaneous oxygen tension was measured at the ankles. Superficial tissue oxyhemoglobin (oxy) and deoxyhemoglobin (deoxy) were measured with hyperspectral imaging from intact tissue bordering the ulcer. A healing index derived from oxy and deoxy values was used to assess the potential for healing.

Results: Fifty-four patients with 73 ulcers completed the study; at 24 weeks, 54 ulcers healed while 19 ulcers did not heal. When using the healing index to predict healing, the sensitivity was 80% (43 of 54), the specificity was 74% (14 of 19), and the positive predictive value was 90% (43 of 48). The sensitivity, specificity, and positive predictive values increased to 86, 88, and 96%, respectively, when removing three false-positive osteomyelitis cases and four false-negative cases due to measurements on a callus. The results indicate that cutaneous tissue oxygenation correlates with wound healing in diabetic patients.

Conclusions: Hyperspectral imaging of tissue oxy and deoxy may predict the healing of DFUs with high sensitivity and specificity based on information obtained from a single visit.

Trial registration: ClinicalTrials.gov NCT00617916.

Figures

Figure 1
Figure 1
Visible and hyperspectral image of a healing DFU taken with the HTOM system. The top panels show a healed DFU case. HTOM values are 75, 34, and 69% for oxy, deoxy, and StO2, respectively. The bottom panels show a nonhealed DFU case. HTOM values are 60, 53, and 53% for oxy, deoxy, and StO2, respectively. Tissue oxygenation is higher in the healed ulcer as seen by the more purplish tone compared with the more cyan/green tone. Mean oxy and deoxy values were determined for each ulcer from an approximate 1-cm–thick band drawn within the periwound area.
Figure 2
Figure 2
A: Oxy and deoxy values for healed and nonhealed DFUs. The diagonal solid line represents the decision line for a healing algorithm based on oxy and deoxy values. Ninety percent of points lying to the right of the line healed. The diagonal dashed line represents a second decision line where 87% of the points (seven of eight excluding calluses) lying to the left of the line did not heal. B: Probability of healing based on HTOM healing index for healed and nonhealed DFUs. An ulcer with a positive healing index has a higher likelihood to heal. ♢, Ulcers with underlying osteomyelitis that did not heal; ♦, ulcers that did not heal at 24 weeks; ○, ulcers that healed and were surrounded by callus; , ulcers that healed at 24 weeks. arb, arbitrary.

References

    1. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047–1053
    1. Reiber GE: The epidemiology of diabetic foot problems. Diabet Med 1996; 13(Suppl. 1):S6–S11
    1. Palumbo PJ, Melton IJ: Peripheral vascular disease and diabetes. In Diabetes in America. 1st ed. Harris MI, Hamman RF. Eds. Washington, DC, U.S. Govt. Printing Office, 1985, p. 401–408 (DHHS publ. no. 85-1468)
    1. Boulton AJM, Armstrong DG, Albert SF, Frykberg RG, Hellman R, Kirkman MS, Lavery LA, LeMaster JW, Mills JL, Sr, Mueller MJ, Sheehan P, Wukich DK: Comprehensive foot examination and risk assessment: a report of the Task Force of the Foot Care Interest Group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care 2008;31:1679–1685
    1. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, Wagner EH: Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999;22:382–387
    1. Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, Hann AW, Hussein A, Jackson N, Johnson KE, Ryder CH, Torkington R, Van Ross ER, Whalley AM, Widdows P, Williamson S, Boulton AJ; the North-West Diabetes Foot Care Study. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002;19:377–384
    1. Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, Lavery LA, Boulton AJM: Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999;22:157–162
    1. Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA: Risk factors for foot infections in individuals with diabetes. Diabetes Care 2006;29:1288–1293
    1. Pecoraro RE, Reiber GE, Burgess EM: Pathways to diabetic limb amputation: basis for prevention. Diabetes Care 1990;13:513–521
    1. Reiber GE, Boyko EJ, Smith DC: Lower extremity foot ulcers and amputations in diabetes. In Diabetes in America. 2nd ed. Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennet PH. Eds. Washington, DC, U.S. Govt. Printing Office, 1995, p. 402–428
    1. Frykberg RG, Armstrong DG, Giurini J, Edwards A, Kravette M, Kravitz S, Ross C, Stavosky J, Stuck R, Vanore J; American College of Foot and Ankle Surgeons. Diabetic foot disorders: a clinical practice guideline. J Foot Ankle Surg 2000;39(Suppl. 5):S1–S60
    1. Harrington C, Zagari MJ, Corea J, Klitenic J: A cost analysis of diabetic lower-extremity ulcers. Diabetes Care 2000;23:1333–1338
    1. Sumpio BE: Foot ulcers. N Engl J Med 2000;343:787–793
    1. Frykberg RG: Diabetic foot ulcers: pathogenesis and management. Am Fam Physician 2002;66:1655–1662
    1. Cobb J, Claremont D: Noninvasive measurement techniques for monitoring of microvascular function in the diabetic foot. Int J Low Extrem Wounds 2002;1:161–169
    1. Zimny S, Dessel F, Ehren M, Pfohl M, Schatz H: Early detection of microcirculatory impairment in diabetic patients with foot at risk. Diabetes Care 2001;24:1810–1814
    1. Ubbink DT, Spincemaille GH, Reneman RS, Jacobs MJ: Prediction of imminent amputation in patients with non-reconstructible leg ischemia by means of microcirculatory investigations. J Vasc Surg 1999;30:114–121
    1. Khaodhiar L, Dinh T, Schomacker KT, Panasyuk SV, Freeman JE, Lew R, Vo T, Panasyuk AA, Lima C, Giurini JM, Lyons TE, Veves A: The use of medical hyperspectral technology to evaluate microcirculatory changes in diabetic foot ulcers and to predict clinical outcomes. Diabetes Care 2007;30:903–910
    1. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26(Suppl. 1):S5–S20
    1. American Diabetes Association and American Academy of Neurology. Report and recommendations of the San Antonio Conference on Diabetic Neuropathy (Consensus Statement). Diabetes Care 1988;11:592–597
    1. Pham H, Armstrong DG, Harvey C, Harkless LB, Giurini JM, Veves A: Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial. Diabetes Care 2000;23:606–611
    1. Zuzak KJ, Schaeberle MD, Lewis EN, Levin IW: Visible reflectance hyperspectral imaging: characterization of a noninvasive, in vivo system for determining tissue perfusion. Anal Chem 2002;74:2021–2028
    1. Beckert S, Witte MB, Königsrainer A, Coerper S: The impact of the Micro-Lightguide O2C for the quantification of tissue ischemia in diabetic foot ulcers. Diabetes Care 2004;27:2863–2867

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit